BioRestorative Therapies ( (BRTX) ) has shared an update.
BioRestorative Therapies, Inc. is set to reveal promising data from its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease at the upcoming International Spine Research Symposium. The company will also host a webcast on November 13, 2024, to discuss these findings, review its third quarter financial results, and provide a business update, offering insights into its ongoing research and financial health.
See more insights into BRTX stock on TipRanks’ Stock Analysis page.
